Can you provide specific patient examples where longitudinal assessment with a combination of tissue-based NGS and ctDNA can provide a more detailed roadmap of targeted therapy?

Can you provide specific patient examples where longitudinal assessment with a combination of tissue-based NGS and ctDNA can provide a more detailed roadmap of targeted therapy?

Can you provide specific patient examples where longitudinal assessment with a combination of tissue-based NGS and ctDNA can provide a more detailed roadmap of targeted therapy?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Prof Frédérique Penault-Llorca, MD

Prof Frédérique Penault-Llorca, MD

Chief Executive Officer
Jean Perrin Comprehensive Cancer Center
Professor of Pathology
Head of the Department of Pathology and Tumor Biology
Clermont-Ferrand, France